GlaxoSmithKline

Green Building Update -- May 8, 2013

by Bryan C. Jackson | Allen Matkins Leck Gamble Mallory & Natsis... on 5/10/2013

Green Building Focus - The ultimate green building eats smog - Bloomberg Businessweek - Apr 26: The Manuel Gea González Hospital in Mexico City has installed a decorative, white facade made from a sophisticated new...more

Supreme Court Denies Certiorari in MAO’s Double Damages Case

by Edward Waller | Fowler White Boggs P.A. on 5/3/2013

On April 15, 2013, the United States Supreme Court denied a petition for certiorari brought by GlaxoSmithKline (“Glaxo”) seeking review of a Third Circuit decision in favor of Humana Medical Plan (“Humana”), as a Medicare...more

Federal Circuit Finds Prosecution History Disclaimer in Enablement Arguments

by Margareta Sorenson | Foley & Lardner LLP on 4/24/2013

In Biogen Idec, Inc. v. GlaxoSmithKline LLC, the Federal Circuit upheld a narrow claim interpretation based on prosecution history disclaimer. The court held that the applicants’ arguments against an enablement rejection...more

Insurance Dispute Freezes Avandia Victims’ Fund [Video]

by Lawyers.com on 4/22/2013

Lawyers.com videojournalist Matt H. Mayes from Los Angeles reports that a big pharma and insurance legal dispute was allowed to deprive innocent victims of money that they were entitled to and often desperately needed. ...more

Biogen Idec, Inc. v. GlaxoSmithKline LLC (Fed. Cir. 2013)

by Donald Zuhn | McDonnell Boehnen Hulbert & Berghoff LLP on 4/18/2013

Yesterday, in Biogen Idec, Inc. v. GlaxoSmithKline LLC, the Federal Circuit affirmed the determination by the District Court for the Southern District of California that the claim term "anti-CD20 antibody" as used in U.S....more

Intellectual Property Bulletin Winter 2013: Murky Waters: Post-Approval Regulatory Activities and the § 271(e)(1) Safe Harbor

by Ewa Davison, David Tellekson | Fenwick & West LLP on 4/5/2013

On January 14, 2013, the U.S. Supreme Court refused to consider the U.S. Court of Appeals for the Federal Circuit's exclusion in Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057 (Fed. Cir. 2011), of post-approval...more

How Does Your Organization Treat Whistleblowers?

by Thomas Fox on 2/8/2013

As almost everyone knows, Lance Armstrong spoke for the first time about his performance enhancing drug (PED) use recently on Oprah. On the first night he admitted for the first time that he used PEDs during his seven wins at...more

Supreme Court Declines Opportunity to Clarify Scope of Hatch-Waxman Safe Harbor

by Loeb & Loeb LLP on 1/17/2013

The U.S. Supreme Court on Jan. 14, 2013, denied GlaxoSmithKline’s petition for certiorari seeking review of the Federal Circuit’s interpretation of the Hatch-Waxman safe-harbor provision at 35 USC 271(e)(1) in Classen...more

Home

Legal News

Find a Lawyer

Browse Subjects

Subscribe

Pro Services

For Reporters

Green Building Update -- May 8, 2013

Supreme Court Denies Certiorari in MAO’s Double Damages Case

Federal Circuit Finds Prosecution History Disclaimer in Enablement Arguments

Insurance Dispute Freezes Avandia Victims’ Fund [Video]

Biogen Idec, Inc. v. GlaxoSmithKline LLC (Fed. Cir. 2013)

Intellectual Property Bulletin Winter 2013: Murky Waters: Post-Approval Regulatory Activities and the § 271(e)(1) Safe Harbor

How Does Your Organization Treat Whistleblowers?

Supreme Court Declines Opportunity to Clarify Scope of Hatch-Waxman Safe Harbor

Insurance Dispute Freezes Avandia Victims’ Fund [Video]

Expand Your Reach